 BMO Capital Markets initiated the coverage on Precision BioSciences Inc NASDAQ: DTIL with an Outperform rating and a price target of 7. The analyst said the thesis is based on: The companys proprietary gene-editing platform, whose mechanism is differentiated in a. 